Update on the molecular pathogenesis and clinical www.impactjournals.com/oncotarget treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network, Leuk Lymphoma, vol.54, pp.699-707, 2013. ,
Treatment of older patients with mantle-cell lymphoma, N Engl J Med, vol.367, pp.520-551, 2012. ,
Molecular pathogenesis of mantle cell lymphoma, J Clin Invest, vol.122, pp.3416-3423, 2012. ,
Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling, Blood, vol.113, pp.3059-69, 2009. ,
Mantle Cell Lymphomas Express a Distinct Genetic Signature Affecting Lymphocyte Trafficking and Growth Regulation as Compared with Subpopulations of Normal Human B Cells, Cancer Res, vol.62, pp.4398-405, 2002. ,
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, pp.787-794, 2001. ,
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents, Cancer Cell, vol.12, pp.171-185, 2007. ,
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor, Cancer Res, vol.68, pp.3421-3428, 2008. ,
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J Clin Oncol, vol.30, pp.488-496, 2012. ,
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, vol.19, pp.202-210, 2013. ,
ABT-199: Taking Dead Aim at BCL-2, Cancer Cell, vol.23, pp.139-141, 2013. ,
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies, Semin Cancer Biol, vol.21, pp.308-312, 2011. ,
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, pp.4604-4613, 2009. ,
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia, Clin Cancer Res, vol.18, pp.487-498, 2012. ,
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia, Blood, vol.113, pp.4403-4413, 2009. ,
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia, Blood, vol.120, pp.3501-3509, 2012. ,
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, vol.107, pp.13075-13080, 2010. ,
ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents, Clin Cancer Res, vol.17, pp.5973-5981, 2011. ,
CD40 regulates the processing of NF-kappaB2 p100 to p52, EMBO J, vol.21, pp.5375-5385, 2002. ,
NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes, Proc Natl Acad Sci, vol.96, pp.9136-9141, 1999. ,
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, pp.507-516, 2013. ,
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, pp.2412-2424, 2013. ,
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced www.impactjournals.com/oncotarget cell death in chronic myeloid leukemia progenitors, Oncotarget, vol.5, pp.9033-9038, 2014. ,
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia, Blood, 2014. ,
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, pp.4111-4120, 2014. ,
Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches, Blood, vol.112, pp.5141-5149, 2008. ,
Do mantle cell lymphomas have an "Achilles heel, Curr Opin Hematol, vol.21, pp.350-357, 2014. ,
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C81S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, pp.1022-1035, 2014. ,
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT, and BCL2 pathways, Br J Haematol, 2014. ,
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma, Br J Cancer, vol.108, pp.1801-1806, 2013. ,